GlassScriptPhysician profile
James A Clark
NPI 1285677781
$635.17
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.16 · 2021: $519 · 2022: $73.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $202.75 | 2020-2022 | |
| Janssen Biotech, INC. | $158.63 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $85.50 | 2021 | |
| Ibsa Pharma INC. | $54.79 | 2021 | |
| Amgen INC. | $34.29 | 2021 | |
| Abbvie INC. | $33.55 | 2021 | |
| Celgene Corporation | $20.07 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $18.51 | 2022 | |
| Genentech USA, INC. | $13.76 | 2021 | |
| Glaxosmithkline, LLC. | $13.32 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.